Home  |  Contact

Cellosaurus J82 (CVCL_0359)

Cell line name J82
Synonyms J-82; J 82; J82COT; J82 COT; J82 CO'T; J82/WT
Accession CVCL_0359
Resource Identification Initiative To cite this cell line use: J82 (RRID:CVCL_0359)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
Part of: UBC-40 urothelial bladder cancer cell line index.
Population: Caucasian; Swedish.
Doubling time: 18 + 5 hours (PubMed=9137463).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (ATCC).
  • Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=2594029; ATCC; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
  • Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; ATCC).
  • Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (PubMed=7787250; PubMed=9850064; ATCC).
HLA typing Source: PubMed=77569
Class I
HLA-AA*02,w32
HLA-BB*05,12
HLA-CC*w02,w03

Source: PubMed=26589293
Class I
HLA-AA*02:01,32:01
HLA-BB*44:02,51:01
HLA-CC*05:01,15:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.13
Native American0
East Asian, North2.62
East Asian, South0
South Asian0.42
European, North70.61
European, South26.21
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8240 (Hu609)CVCL_4V98 (J82-NVB)CVCL_C8D4 (J82/MMC)
Originate from same individual CVCL_5H97 ! J82-EBV
Sex of cell Male
Age at sampling 58Y
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; Cosmic-CLP; KCLB; PubMed=11416159; PubMed=27270441

Markers:
AmelogeninX,Y
CSF1PO10,11
D2S133819
D3S135816,18
D5S81812,13
D7S8209,11
D8S11798,13
D13S31710,12 (ATCC; CCRID; Cosmic-CLP; KCLB)
12 (PubMed=27270441)
D16S53911,12
D18S5112
D19S43312,13
D21S1130 (CCRID)
30,31 (PubMed=11416159)
FGA20,24
TH019.3
TPOX11,12
vWA17,18

Run an STR similarity search on this cell line
Web pages https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-250.html
https://www.synapse.org/UC25
Publications

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=864752; DOI=10.1093/jnci/58.6.1743
Marshall C.J., Franks L.M., Carbonell A.W.
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.
J. Natl. Cancer Inst. 58:1743-1751(1977)

PubMed=870558; DOI=10.1177/25.4.870558
Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.
Alkaline phosphatase activity in human bladder tumor cell lines.
J. Histochem. Cytochem. 25:266-274(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=571047
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl. Cancer Inst. Monogr. 49:5-9(1978)

PubMed=687519; DOI=10.1038/bjc.1978.164
O'Toole C.M., Price Z.H., Ohnuki Y., Unsgaard B.
Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma.
Br. J. Cancer 38:64-76(1978)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6823318; DOI=10.1038/301429a0
O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.
Identity of some human bladder cancer cell lines.
Nature 301:429-430(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=4057431; DOI=10.1016/s0022-5347(17)47713-5
Bishai M.B., Kagawa S., Narayan K.S., Jones L.W., Kirk D.
Growth of a malignant human urothelial cell line (J82) in a serum-free medium (HMRI-1) developed previously for normal human urothelium.
J. Urol. 134:1287-1290(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=3413074; DOI=10.1073/pnas.85.16.6042
Pereira-Smith O.M., Smith J.R.
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988)

PubMed=2594029; DOI=10.1056/NEJM198912213212501
Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D., Little J.B., McConkie-Rosell A., Buckley E.G., Dryja T.P.
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling.
N. Engl. J. Med. 321:1689-1695(1989)

PubMed=7787250
Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J., Lippa M., Hatzivassiliou G., Tan J.
p53 mutations in bladder carcinoma cell lines.
Oncol. Res. 6:569-579(1994)

PubMed=8077054; DOI=10.1002/ijc.2910580512
Xu B.H., Gupta V., Singh S.V.
Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
Int. J. Cancer 58:686-692(1994)

PubMed=9137463
Debal V., Breillout F., Manfait M.
Concomitant decrease of resistance and modifications of the cytoskeleton after all-trans retinoic acid and phorbol ester treatments in a navelbine-resistant bladder carcinoma cell line.
Anticancer Res. 17:1147-1154(1997)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11921286; DOI=10.1002/gcc.10050
Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Genes Chromosomes Cancer 34:86-96(2002)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=14762065; DOI=10.1101/gr.2012304
Bignell G.R., Huang J., Greshock J., Watt S., Butler A.P., West S., Grigorova M., Jones K.W., Wei W., Stratton M.R., Futreal P.A., Weber B., Shapero M.H., Wooster R.
High-resolution analysis of DNA copy number using oligonucleotide microarrays.
Genome Res. 14:287-295(2004)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403.1-403.16(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; HTB-1
CCTCC; GDC0225
CLS; 305055
KCB; KCB 2014052YJ
KCLB; 30001
Cell line databases/resources CLO; CLO_0007006
MCCL; MCC:0000253
cancercelllines; CVCL_0359
CCRID; 1101HUM-PUMC000346
CCRID; 3101HUMTCHu218
CCRID; 4201HUM-CCTCC00225
Cell_Model_Passport; SIDM00693
Cosmic-CLP; 753566
DepMap; ACH-000396
IGRhCellID; J82
LINCS_LDP; LCL-1714
Anatomy/cell type resources BTO; BTO:0001671
Biological sample resources BioSample; SAMN03471085
BioSample; SAMN10987788
Chemistry resources ChEMBL-Cells; CHEMBL3308508
ChEMBL-Targets; CHEMBL614586
GDSC; 753566
PharmacoDB; J82_675_2019
PubChem_Cell_line; CVCL_0359
Encyclopedic resources Wikidata; Q54898490
Experimental variables resources EFO; EFO_0002210
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM136231
GEO; GSM492491
GEO; GSM827204
GEO; GSM887167
GEO; GSM888239
GEO; GSM1374575
GEO; GSM1574579
GEO; GSM1669946
Polymorphism and mutation databases Cosmic; 753566
Cosmic; 755399
Cosmic; 760474
Cosmic; 808517
Cosmic; 809378
Cosmic; 845571
Cosmic; 846276
Cosmic; 867838
Cosmic; 943731
Cosmic; 1016887
Cosmic; 1046674
Cosmic; 1093984
Cosmic; 1175827
Cosmic; 1285119
Cosmic; 1285996
Cosmic; 1302362
Cosmic; 1927308
Cosmic; 1995459
Cosmic; 2050445
Cosmic; 2057450
Cosmic; 2444229
Cosmic; 2686097
Cosmic; 2700997
IARC_TP53; 3721
IARC_TP53; 21416
LiGeA; CCLE_551
Progenetix; CVCL_0359
Proteomic databases PRIDE; PXD030304
PRIDE; PXD032049
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number42